SPHERE Trial: Splenomegaly and Morbidity in Tanzanian Children with Sickle Cell Anemia

25% of Tanzanian children with sickle cell anemia had palpable splenomegaly at enrollment in the SPHERE trial. The supplementary material likely contains longitudinal clinical data from 53 children over 221 patient-years, analyzing the persistence of splenomegaly and its association with adverse events. The data was uploaded by figshare admin karger in April 2026.

Use Cases

• Analyze the association between persistent splenomegaly and adverse events based on incidence rate ratios
• Compare hydroxyurea dosing and clinical outcomes between splenomegaly categories based on hemoglobin and HbF levels
• Study the prevalence of splenomegaly in pediatric sickle cell anemia using palpation and ultrasound measurements

Strengths

• Data originates from a named clinical trial (SPHERE Trial NCT03948867)
• Includes longitudinal categorization of splenomegaly over 221 patient-years of treatment
• Contains specific statistical comparisons (e.g., IRR=7.1 for transfusions)

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment
• The dataset is very small (15.2 KB), indicating limited scope

Provenance

Source

figshare admin karger

Collection Method

Secondary analysis of the SPHERE trial, an open-label trial of dose-escalated hydroxyurea

Freshness

Last updated 2026-04-24 05:55:18; freshness should be verified

Geography

Tanzania